FGF-1 for Intramuscular Injection for the Treatment of Peripheral Arterial Disease

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE1/PHASE2

Total Enrollment

24 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-12-31

Study Completion Date

2022-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

FGF-1 for the treatment of patients with peripheral arterial disease with intermittent claudication.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Gene Expression and Tolerability Study of NV1FGF in Patients With Peripheral Artery Occlusive Disease Planned to Undergo Major Amputation

NCT01157143

Peripheral Arterial Occlusive Disease

COMPLETED PHASE1

Fibroblast Growth Factor-1 (FGF-1) for the Treatment of Coronary Heart Disease

NCT00117936

Coronary Disease Coronary Heart Disease Myocardial Ischemia +1 more

UNKNOWN PHASE2

Safety and Tolerability of NV1FGF in Patients With Severe Peripheral Artery Occlusive Disease

NCT01157156

Peripheral Arterial Occlusive Disease

COMPLETED PHASE1

Prospective Carotid Artery Stenosis Trial

NCT05724836

Patients With Any Degree of Carotid Artery Stenosis and Vulnerable Features in the Carotid Artery Plaque

RECRUITING

Prostaglandin E1 in Outpatients With Intermittent Claudication

NCT01263925

Stage II Peripheral Arterial Occlusive Disease Intermittent Claudication Fontaine Stage II PAOD

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

FGF-1 administered by intramuscular injection for the treatment of peripheral arterial disease with intermittent claudication. Eligible patients are allocated to one of three treatment arms. Patients within each dosing group will be randomized between study drug and vehicle control. Safety, pharmacokinetics, and cardiovascular improvement will be evaluated at day 1 and weeks 1, 4 and 12 post dosing.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Peripheral Arterial Disease Stenosis Intermittent Claudication

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Placebo

The dosing groups correspond to total doses of 0 µg/kg of FGF-1.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Vehicle: 0 µg/kg

Human FGF-1

The dosing groups correspond to total doses of either 3, 10 or 30 µg/kg of FGF-1.

Group Type ACTIVE_COMPARATOR

FGF-1

Intervention Type DRUG

Doses of FGF-1: 3 ug/kg; 10 ug/kg; 30 ug/kg

Low dose: 3.0 μg/kg Mid dose: 10 μg/kg High dose: 30 µg/kg

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

FGF-1

Doses of FGF-1: 3 ug/kg; 10 ug/kg; 30 ug/kg

Low dose: 3.0 μg/kg Mid dose: 10 μg/kg High dose: 30 µg/kg

Intervention Type DRUG

Placebo

Vehicle: 0 µg/kg

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Acidic FGF

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Subjects considered eligible to enter the study must sign an informed consent form prior to the initiation of any study procedures. In the event that the subject must be withdrawn and is re-screened for study participation at a later date, a new informed consent form must be signed. Subjects must be competent to give written informed consent.
2. Age must be ≥50 and ≤75 years of age with a life expectancy of \> 1 year and leg survival \> 6 months. Patients \>75 and ≤80 years of age will be considered if they show no signs of cognitive or muscle function decline and are fully able to comply with the protocol.
3. Patients must have experienced intermittent claudication for at least 6 months and have been stable for the past 3 months.
4. Patients must have peripheral arterial disease, as confirmed by a resting ABI ≥0.40 and \<0.90 based on at least one leg as measured using both the dorsal pedis and posterior tibial arteries.
5. Stenosis of \>70% up to total occlusion must be present in the popliteal artery and/or in the tibial peroneal trunk or at least 2 tibial arteries above the ankle without inflow limitation of the popliteal artery. Adequate popliteal inflow is defined as continuous flow from the abdominal aorta, iliac, common femoral and superficial femoral with any stenosis \< 50% as determined either by intra-arterial DSA, CTA or Gd CE-MRA.
6. The screening Gardner treadmill test peak walking times (PWT) must be \>1 minute and \< 12 minutes and limited by pain in one or both calves.
7. Preexisting medication regime must be stable for 6 weeks preceding dosing.

Exclusion Criteria

1. Evidence of critical leg ischemia, i.e. ischemic rest pain or ischemic ulceration
2. Treadmill walking limited by conditions other than intermittent claudication including arthritis, angina and dyspnea
3. Lower limb amputation of, or in, either leg including toes
4. Evidence of limb ischemia from immunologic or inflammatory disorders
5. Leg surgery or revascularization within past 6 months or peripheral angioplasty within past 3 months or anticipated during study
6. Participation in any investigational device or drug trial within the past 6 months
7. Myocardial infarction, unstable angina, stroke or ischemic attack within past 6 months
8. New York Heart Association (NYHA) class II, III or IV heart failure, restrictive or hypertrophic cardiomyopathy or severe valvular disease
9. QTc elongation greater than 450 ms in males or 460 ms in females
10. PT (INR), PTT, urinalysis, thyroid function (T3, T4, TSH) outside normal limits
11. Hemorrhage or thrombotic events (e.g. deep vein thrombosis) within past 6 months
12. Thrombocytopenia (\<100,000/µl), history of heparin-induced thrombocytopenia
13. Major surgery with the past 6 months
14. Positive proliferative retinopathy exam
15. Present of any type of cancer or history of cancer except past (but not present) basal cell dermal carcinoma not on either leg
16. Inflammatory or progressive fibrotic or myelofibrotic disorders
17. Patients experiencing bacterial or viral infection (e.g. hepatitis or HIV) or who may otherwise be febrile
18. Hemoglobin A1c(HgbA1c) of \>8%
19. Type I diabetes
20. Total fasting cholesterol \>200
21. Uncontrolled hypertension (≥160 systolic or ≥100 diastolic pressure) or hypotension (\<90 systolic or \<60 diastolic pressure)
22. Disease or drug (e.g. systemic corticosteroid) immuno-compromised
23. Hepatic dysfunction as defined either by AST or ALT \> 2.0 times the upper limit of normal
24. Serum creatinine of ≥ 2.5 mg/dl
25. Proteinuria (urine protein/creatinine ratio \> 3)
26. Antiproliferative drugs (e.g. thalidomide, hydroxyurea)
27. Radiation therapy
28. Implanted devices not compatible with strong magnetic fields
29. Life expectance of less than 1 year
30. Females who are premenopausal and not sterilized or using adequate birth control or are either pregnant, intend to become pregnant or are nursing

Minimum Eligible Age

50 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No